JP2020501513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501513A5 JP2020501513A5 JP2019517069A JP2019517069A JP2020501513A5 JP 2020501513 A5 JP2020501513 A5 JP 2020501513A5 JP 2019517069 A JP2019517069 A JP 2019517069A JP 2019517069 A JP2019517069 A JP 2019517069A JP 2020501513 A5 JP2020501513 A5 JP 2020501513A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- construct
- toxin
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662401195P | 2016-09-29 | 2016-09-29 | |
| US201662401192P | 2016-09-29 | 2016-09-29 | |
| US62/401,195 | 2016-09-29 | ||
| US62/401,192 | 2016-09-29 | ||
| PCT/IL2017/051094 WO2018061004A1 (en) | 2016-09-29 | 2017-09-27 | Therapeutic multi-targeting constructs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020501513A JP2020501513A (ja) | 2020-01-23 |
| JP2020501513A5 true JP2020501513A5 (https=) | 2020-11-12 |
| JP7133225B2 JP7133225B2 (ja) | 2022-09-08 |
Family
ID=61763358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517069A Active JP7133225B2 (ja) | 2016-09-29 | 2017-09-27 | 治療用多標的コンストラクトおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11739163B2 (https=) |
| EP (1) | EP3518953A4 (https=) |
| JP (1) | JP7133225B2 (https=) |
| CN (1) | CN109789183A (https=) |
| AU (2) | AU2017333442A1 (https=) |
| CA (1) | CA3037261A1 (https=) |
| IL (1) | IL265236B2 (https=) |
| WO (1) | WO2018061004A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11739163B2 (en) * | 2016-09-29 | 2023-08-29 | Aebi Ltd. | Therapeutic multi-targeting constructs and uses thereof |
| US20210198319A1 (en) * | 2017-09-27 | 2021-07-01 | Aebi Ltd. | Cytotoxic peptides and conjugates thereof |
| KR102268983B1 (ko) | 2019-09-11 | 2021-06-24 | 경북대학교 산학협력단 | 엔도테린 수용체 억제제에 의한 엑소좀 분비 억제 또는 pd-l1 발현 억제 용도 |
| CN112252362A (zh) * | 2020-10-10 | 2021-01-22 | 无锡市市政设施建设工程有限公司 | 基于bim实现地铁车站主体结构盘扣支架搭设的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040058865A1 (en) | 2001-11-26 | 2004-03-25 | Danishefsky Samuel J | Homing peptide multimers, their preparation and uses |
| ES2396368T3 (es) | 2003-03-03 | 2013-02-21 | Dyax Corporation | Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos |
| WO2005090393A2 (en) | 2004-02-09 | 2005-09-29 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Multimeric protein toxins to target cells having multiple identifying characteristics |
| ATE524579T1 (de) | 2005-07-21 | 2011-09-15 | Aebi Ltd | Verfahren und zusammensetzungen zur identifizierung eines peptids mit intermolekularer wechselwirkung mit einem interessierenden ziel |
| AU2006323415A1 (en) | 2005-12-06 | 2007-06-14 | Domantis Limited | Bispecific ligands with binding specificity to cell surface targets and methods of use therefor |
| WO2007093373A2 (en) | 2006-02-14 | 2007-08-23 | Università Degli Studi Di Siena | Branched multimeric peptides for tumor diagnosis and therapy |
| US20080131428A1 (en) * | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| PE20081140A1 (es) | 2006-10-25 | 2008-09-22 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
| WO2008079973A2 (en) * | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Egfr binding peptides and uses thereof |
| KR20100052545A (ko) | 2007-08-28 | 2010-05-19 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물 |
| AU2009213141A1 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
| EP2352522A4 (en) | 2008-11-06 | 2014-03-05 | Univ Washington | BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE |
| JP2010154842A (ja) * | 2008-12-03 | 2010-07-15 | Koji Kawakami | Ｅｇｆｒを標的にした新規抗がんキメラペプチド |
| WO2010083495A2 (en) | 2009-01-18 | 2010-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrin |
| WO2011047135A2 (en) * | 2009-10-14 | 2011-04-21 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treating bladder cancer |
| DK2547355T3 (en) | 2010-03-19 | 2017-03-20 | Baxalta GmbH | TFPI INHIBITORS AND METHODS OF USE |
| EP2714738B1 (en) * | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| CA2865243A1 (en) | 2012-02-23 | 2013-08-29 | President And Fellows Of Harvard College | Modified microbial toxin receptor for delivering agents into cells |
| PL3489254T3 (pl) * | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| JP6103832B2 (ja) | 2012-06-25 | 2017-03-29 | Hoya株式会社 | Ｅｇｆｒ結合性ペプチド |
| CA2902830C (en) | 2013-03-12 | 2023-09-19 | Biocon Ltd. | Fusion immunomodulatory proteins and methods for making same |
| EP3022222A4 (en) | 2013-07-18 | 2017-06-07 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
| US10786497B2 (en) | 2013-08-16 | 2020-09-29 | Equip, Llc | Discrete PEG constructs |
| WO2015195721A1 (en) * | 2014-06-16 | 2015-12-23 | Purdue Research Foundation | Compositions and methods for treating cancer |
| US11739163B2 (en) * | 2016-09-29 | 2023-08-29 | Aebi Ltd. | Therapeutic multi-targeting constructs and uses thereof |
| US20210198319A1 (en) | 2017-09-27 | 2021-07-01 | Aebi Ltd. | Cytotoxic peptides and conjugates thereof |
| US20200339629A1 (en) | 2019-04-24 | 2020-10-29 | Aebi Ltd. | Therapeutic constructs comprising cmet binding peptides |
-
2017
- 2017-09-27 US US16/337,163 patent/US11739163B2/en active Active
- 2017-09-27 EP EP17855166.9A patent/EP3518953A4/en active Pending
- 2017-09-27 WO PCT/IL2017/051094 patent/WO2018061004A1/en not_active Ceased
- 2017-09-27 CN CN201780060289.8A patent/CN109789183A/zh active Pending
- 2017-09-27 AU AU2017333442A patent/AU2017333442A1/en not_active Abandoned
- 2017-09-27 JP JP2019517069A patent/JP7133225B2/ja active Active
- 2017-09-27 CA CA3037261A patent/CA3037261A1/en active Pending
- 2017-09-27 IL IL265236A patent/IL265236B2/en unknown
-
2022
- 2022-08-24 AU AU2022221434A patent/AU2022221434A1/en not_active Abandoned
-
2023
- 2023-07-06 US US18/348,229 patent/US20240002547A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Teesalu et al. | C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration | |
| Shin et al. | Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy | |
| JP2020501513A5 (https=) | ||
| JP2021502810A5 (https=) | ||
| ES2926511T3 (es) | Anticuerpos anti-CLEVER-1 humanizados y utilización de los mismos | |
| EP3091028A1 (en) | Fibronectin based scaffold proteins having improved stability | |
| RU2012147960A (ru) | Trail r2-специфические мультимерные скаффолды | |
| JP2021508449A5 (https=) | ||
| Zhang et al. | Functional antibody CDR3 fusion proteins with enhanced pharmacological properties | |
| JP2013541335A5 (https=) | ||
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2019501973A5 (https=) | ||
| US11377501B2 (en) | Peptide having high affinity for PD-L1 protein and use thereof | |
| Song et al. | Arginines in the CDR of anti‐dsDNA autoantibodies facilitate cell internalization via electrostatic interactions | |
| CN112641953A (zh) | 一种靶向功能分子修饰的抗体复合物 | |
| Zhang et al. | Human Serum Albumin‐Based Drug‐Free Macromolecular Therapeutics: Apoptosis Induction by Coiled‐Coil‐Mediated Cross‐Linking of CD20 Antigens on Lymphoma B Cell Surface | |
| CN117924516B (zh) | 一种提高adc药物疗效的重组蛋白及其应用 | |
| CN107223136A (zh) | 一种将抗体导入细胞内的方法 | |
| Liu et al. | A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity | |
| JP2023528454A5 (https=) | ||
| JP2020501513A (ja) | 治療用多標的コンストラクトおよびその使用 | |
| CN113444182A (zh) | 一种靶向递送IgG类抗体的融合蛋白载体及其用途 | |
| Kim et al. | Bispecific anti-mPDGFRβ x cotinine scFv-Cκ-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFRβ expressing cells | |
| Wang et al. | Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab | |
| US20260103541A1 (en) | Paracrine Adenoviral Delivery of Biomolecules |